Recombinant human C1-inhibitor in the treatment of acute angioedema attacks.
about
Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiencyTherapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage.Management of upper airway edema caused by hereditary angioedema.HAE therapies: past present and future.Management of acute attacks of hereditary angioedema: potential role of icatibant.Recombinant and plasma-purified human c1 inhibitor for the treatment of hereditary angioedema.Recent developments in the treatment of acute abdominal and facial attacks of hereditary angioedema: focus on human C1 esterase inhibitor.Treatment of hereditary angioedema with plasma-derived C1 inhibitorClinical Immunology Review Series: An approach to the patient with angio-oedema.Therapeutic approaches in hereditary angioedema.rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency.Conestat alfa for the treatment of angioedema attacks.The new era of C1-esterase inhibitor deficiency therapy.Target levels of functional C1-inhibitor in hereditary angioedema.Progress in the emergency management of hereditary angioedema: focus on new treatment options in the United States.Recombinant human c1 inhibitor (conestat alfa): in the treatment of angioedema attacks in hereditary angioedema.Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment.Treatment of type I and II hereditary angioedema with Rhucin, a recombinant human C1 inhibitor.Pasteurized C1 inhibitor concentrate in hereditary angioedema: pharmacology, safety, efficacy and future directions.Hereditary Angioedema Attacks: Local Swelling at Multiple Sites.Immunosafety of recombinant human C1-inhibitor in hereditary angioedema: evaluation of ige antibodies.Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study.Summary of the International Multicenter Prospective Angioedema C1-inhibitor Trials 1 and 2 (IMPACT1 and 2).Immunogenicity assessment of recombinant human c1-inhibitor: an integrated analysis of clinical studies.C-reactive protein levels in hereditary angioedema.[Diagnostics and exclusion of hereditary angioedema : a standarized approach for the practice].New promise and hope for treating hereditary angioedema
P2860
Q26801368-D0354241-6D3D-46AC-A214-FEECC78A1F25Q33745120-64682245-4798-437B-8392-9B3C3D9937F2Q34060670-D04A5114-03A2-4A36-9336-9DF28D2097A5Q34063768-8D1E6FF2-D33B-480E-8A3B-E149F1B44B10Q34139106-7042D9B8-6D72-46C0-BAA9-234102B7EBD5Q36882540-47CA6FC3-C51B-40E0-8C63-DF869FD0E001Q36925176-542F883D-1DC8-4897-94A0-957E08762261Q37052806-969F6B00-66D2-41AC-8F76-384FEE867D5EQ37394385-EFA267C7-EE03-443B-8F43-35FFD88FB422Q37833531-F32910FB-46D0-4915-B4D0-40327A50F46AQ37855944-AB29C87B-0351-47F1-914E-4D9E4DE670E8Q37900837-ADD2A740-F32F-48F5-AC1E-1FCF08278D00Q37915379-4DBFCB58-7F20-440C-9572-60AC347D50AEQ37933448-02BA244E-B950-4234-8F05-6090C0BBA9B3Q38018214-526F5AEC-F509-47E0-8501-3BEED714AA82Q38040455-C71B8BE7-1D29-45DE-B69C-ADD47D1847CBQ38351120-322B2F2E-9F6C-488C-AAAC-862A866E2538Q38790498-E40AD89B-4C6A-46F7-A895-A71A1C44512EQ40031791-D056975B-9586-406F-B31A-879BB4C386C6Q40139193-FED0818B-D817-4EF9-86F4-A19407167C40Q41665838-2B970412-442E-4BE3-94F3-983CEB8D8AE5Q44452633-58CC25C8-F8E3-4158-9571-B316E393D10DQ44493553-FD8FB76D-611C-4766-AFE3-3A072719EFAAQ45329636-608C8D8F-1844-430E-AB1C-6BAE596B2AE0Q45935551-B9589F2B-799C-4CD0-9713-301261F195FCQ46519532-AF065E2C-42FF-4E1A-9B53-065B9AF5A4F7Q52887682-5E4791CF-B9BA-4277-87C2-3C50DC01BA7FQ58615572-24BDDD48-64EB-4F7F-96BE-8B6CDAB9D753
P2860
Recombinant human C1-inhibitor in the treatment of acute angioedema attacks.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Recombinant human C1-inhibitor in the treatment of acute angioedema attacks.
@en
Recombinant human C1-inhibitor in the treatment of acute angioedema attacks.
@nl
type
label
Recombinant human C1-inhibitor in the treatment of acute angioedema attacks.
@en
Recombinant human C1-inhibitor in the treatment of acute angioedema attacks.
@nl
prefLabel
Recombinant human C1-inhibitor in the treatment of acute angioedema attacks.
@en
Recombinant human C1-inhibitor in the treatment of acute angioedema attacks.
@nl
P2093
P2860
P50
P1433
P1476
Recombinant human C1-inhibitor in the treatment of acute angioedema attacks
@en
P2093
Barbara Bilo
C Erik Hack
Greg Porebski
Jan Nuijens
Krystyna Obtulowicz
Marcel Levi
P2860
P304
P356
10.1111/J.1537-2995.2007.01239.X
P577
2007-06-01T00:00:00Z